Recombinant human FSH and recombinant human LH in a 2:1 ratio combination: a new tool for ovulation induction

References

• Reame NE, Sauder ED, Case GD, Kelch RP, Marshall JC. Pulsatile gonadotropin secretion in women with hypothalamic amenorrhea: evidence that reduced frequency of gonadotropin releasing hormone secretion is the mechanism of persistant anovulation. J. Clin. Endocrinol. Metab.61, 851–858 (1985).
   PubMed Web of Science ®Google Scholar
• Couzinet B, Lestrat N, Brailly S, Forest M, Schaison G. Stimulation of ovarian follicular maturation with pure follicle stimulating hormone in women with gonadotropin deficiency. J. Clin. Endocrinol. Metab.66, 552–556 (1988).
   PubMed Web of Science ®Google Scholar
• Ryan RJ, Charlesworth MC, McCormick DJ, Milius RP, Keutmann HT. The glycoprotein hormones: recent studies of structure–function relationships. FASEB J.2, 2661–2669 (1988)
   PubMed Web of Science ®Google Scholar
• Driebergen R, Baer G. Quantification of follicle stimulating hormone (follitropin a): is in vivo bioassay still relevant in the recombinant age? Curr. Med. Res. Opin.19, 41–46 (2003).
   PubMed Web of Science ®Google Scholar
• Bassett RM, Driebergen R. Continued improvements in the quality and consistency of follitropin-α, recombinant human FSH. Reprod. Biomed. Online10, 169–177 (2005).
   PubMed Web of Science ®Google Scholar
• Liu HC, He Z, Rosenwaks Z. In vitro culture and in vitro maturation of mouse preantral follicles with recombinant gonadotropins. Fertil Steril.77, 373–383 (2002).
   PubMed Web of Science ®Google Scholar
• Karnitis VJ, Townson DH, Friedman CI, Danforth DR. Recombinant human follicle-stimulating hormone stimulates multiple follicular growth, but minimal estrogen production in gonadotropin-releasing hormone antagonist-treated monkeys: examining the role of luteinizing hormone in follicular development and steroidogenesis. J. Clin. Endocrinol. Metab.79, 91–97 (1994).
   PubMed Web of Science ®Google Scholar
• The European Recombinant Human LH Study Group. Recombinant human luteinizing hormone (LH) to support recombinant follicle stimulating hormone (FSH)-induced follicular development in LH- and FSH-deficient anovulatory women: a dose finding study. J. Clin. Endocrinol. Metab.83, 1507–1514 (1998).
   PubMed Web of Science ®Google Scholar
• Porchet HC, le Cotonnec JY, Loumaye E. Clinical pharmacology of recombinant human follicle-stimulating hormone. III. Pharmacokinetic–pharmacodynamic modeling after repeated subcutaneous administration. Fertil Steril.61, 687–695 (1994).
   PubMed Web of Science ®Google Scholar
• le Cotonnec JY, Porchet HC, Beltrami V, Khan A, Toon S, Rowland M. Clinical pharmacology of recombinant human follicle-stimulating hormone (FSH). I. Comparative pharmacokinetics with urinary human FSH. Fertil Steril.61, 669–678 (1994)
   PubMed Web of Science ®Google Scholar
• le Cotonnec JY, Porchet HC, Beltrami V, Munafo A. Clinical pharmacology of recombinant human luteinizing hormone: part I. Pharmacokinetics after intravenous administration to healthy female volunteers and comparison with urinary human luteinizing hormone. Fertil Steril.69, 189–194 (1998).
   PubMed Web of Science ®Google Scholar
• le Cotonnec JY, Porchet HC, Beltrami V, Munafo A. Clinical pharmacology of recombinant human luteinizing hormone: part II. Bioavailability of recombinant human luteinizing hormone assessed with an immunoassay and an in vitro bioassay. Fertil Steril.69, 195–200 (1998).
   PubMed Web of Science ®Google Scholar
• le Cotonnec JY, Loumaye E, Porchet HC, Beltrami V, Munafo A. Pharmacokinetic and pharmacodynamic interactions between recombinant human luteinizing hormone and recombinant human follicle-stimulating hormone. Fertil Steril.69, 201–209 (1998).
   PubMed Web of Science ®Google Scholar
• Picard M, Rossier C, Papasouliotis O, Lugan I. Bioequivalence of recombinant human FSH and recombinant human LH in a fixed 2:1 combination: two Phase I, randomized, crossover studies. Curr. Med. Res. Opin.24, 1199–208 (2008).
   PubMed Web of Science ®Google Scholar
• Balasch J, Miró F, Burzaco I et al. The role of luteinizing hormone in human follicle development and oocyte fertility: evidence from in-vitro fertilization in a woman with long-standing hypogonadotrophic hypogonadism and using recombinant human follicle stimulating hormone. Hum. Reprod.10, 1678–1683 (1995).
   PubMed Web of Science ®Google Scholar
• Mochtar MH, Van der Veen, Ziech M, van Wely M. Recombinant luteinizing hormone (rLH) for controlled ovarian hyperstimulation in assisted reproductive cycles. Cochrane Database Syst Rev.18(2), CD005070 (2007).
   Google Scholar
• Chappel SC, Howles C. Reevaluation of the roles of luteinizing hormone and follicle-stimulating hormone in the ovulatory process. Hum. Reprod.6, 1206–1212 (1991).
   PubMed Web of Science ®Google Scholar
• Kolibianakis EM, Collins J, Tarlatzis B, Papanikolaou E, Devroey P. Are endogenous LH levels during ovarian stimulation for IVF using GnRH analogues associated with the probability of ongoing pregnancy? A systematic review. Hum. Reprod. Update.12, 3–12 (2006).
   PubMed Web of Science ®Google Scholar
• Marrs R, Meldrum D, Muasher S, Schoolcraft W, Werlin L, Kelly E. Randomized trial to compare the effect of recombinant human FSH (follitropin-α) with or without recombinant human LH in women undergoing assisted reproduction treatment. Reprod. Biomed. Online8, 175–182 (2004).
   PubMed Web of Science ®Google Scholar
• Humaidan P, Bungum M, Bungum L, Yding Andersen C. Effects of recombinant LH supplementation in women undergoing assisted reproduction with GnRH agonist down-regulation and stimulation with recombinant FSH: an opening study. Reprod. Biomed. Online8, 635–643 (2004).
   PubMed Web of Science ®Google Scholar
• Fábregues F, Creus M, Peñarrubia J, Manau D, Vanrell JA, Balasch J. Effects of recombinant human luteinizing hormone supplementation on ovarian stimulation and the implantation rate in down-regulated women of advanced reproductive age. Fertil Steril.85, 925–931 (2006).
   PubMed Web of Science ®Google Scholar
• Nyboeandersen A, Humaidan P, Fried G et al; Nordic LH Study Group. Recombinant LH supplementation to recombinant FSH during the final days of controlled ovarian stimulation for in vitro fertilization. A multicentre, prospective, randomized, controlled trial. Hum. Reprod.23, 427–434 (2008).
   PubMed Web of Science ®Google Scholar
• Griesinger G, Schultze-Mosgau A, Dafopoulos K et al. Recombinant luteinizing hormone supplementation to recombinant follicle-stimulating hormone induced ovarian hyperstimulation in the GnRH-αntagonist multiple-dose protocol. Hum. Reprod.20, 1200–1206 (2005).
   PubMed Web of Science ®Google Scholar
• Cédrin-Durnerin I, Grange-Dujardin D, Laffy A et al. Recombinant human LH supplementation during GnRH antagonist administration in IVF/ICSI cycles: a prospective randomized study. Hum. Reprod.19, 1979–1984 (2004).
   PubMed Web of Science ®Google Scholar
• Levi-Setti PE, Cavagna M, Bulletti C. Recombinant gonadotrophins associated with GnRH antagonist (cetrorelix) in ovarian stimulation for ICSI: comparison of r-FSH alone and in combination with r-LH. Eur. J. Obstet. Gynecol. Reprod. Biol.1(126), 212–216 (2006).
   Google Scholar
• Lisi F, Rinaldi L, Fishel S, Lisi R, Pepe GP, Picconeri MG. Use of recombinant follicule-stimulating hormone (Gonal F) and a recombinant luteinizing hormone (Luveris) in multiple follicular stimulation in patients with a suboptimal response to in vitro fertilization. Fertil Steril.79, 1037–1038 (2003).
   PubMed Web of Science ®Google Scholar
• Ferraretti AP, Gianaroli L, Magli MC, D’angelo A, Farfalli V, Montanaro N. Exogenous luteinizing hormone in controlled ovarian hyperstimulation for assisted reproduction techniques. Fertil Steril.82, 1521–1526 (2004).
   PubMed Web of Science ®Google Scholar
• De Placido G, Alviggi C, Perino A et al.; Italian Collaborative Group on Recombinant Human Luteinizing Hormone. Recombinant human LH supplementation versus recombinant human FSH (rFSH) step-up protocol during controlled ovarian stimulation in normogonadotrophic women with initial inadequate ovarian response to rFSH. A multicentre, prospective, randomized controlled trial. Hum. Reprod.20, 390–396 (2005).
   PubMed Web of Science ®Google Scholar
• De Placido G, Mollo A, Clarizia R, Strina I, Conforti S, Alviggi C. Gonadotropin-releasing hormone (GnRH) antagonist plus recombinant luteinizing hormone vs. a standard GnRH agonist short protocol in patients at risk for poor ovarian response. Fertil Steril.85, 247–250 (2006).
   PubMed Web of Science ®Google Scholar
• Klein NA, Battaglia DE, Fujimoto VY, Davis GS, Bremner WJ, Soules MR. Reproductive aging: accelerated ovarian follicular development associated with a monotropic follicle-stimulating hormone rise in normal older women. J. Clin. Endocrinol. Metab.81, 1038–1045 (1996).
   PubMed Web of Science ®Google Scholar
• Davison SL, Bell R, Donath S, Montalto JG, Davis SR. Androgen levels in adult females: changes with age, menopause, and oophorectomy. J. Clin. Endocrinol. Metab.90, 3847–3853 (2005).
   PubMed Web of Science ®Google Scholar
• Coomarasamy A, Afnan M, Cheema D, van der Veen F, Bossuyt PM, van Wely M. Urinary hMG versus recombinant FSH for controlled ovarian hyperstimulation following an agonist long down-regulation protocol in IVF or ICSI treatment: a systematic review and meta-αnalysis. Hum. Reprod.23, 310–315 (2008).
   PubMed Web of Science ®Google Scholar
• Bosch E, Vidal C, Labarta E, Simon C, Remohí J, Pellicer A. Highly purified hMG versus recombinant FSH in ovarian hyperstimulation with GnRH antagonists – a randomized study. Hum. Reprod.23(10), 2346–2351 (2008).
   PubMed Web of Science ®Google Scholar
• Bosch E, Pau E, Albert C, Zuzuarregui JL, Remohí J, Pellicer A. Impact of LH administration on oocyte quality and embryo morphology. Fertil Steril.86(Suppl. 2), S425 (2006).
   Google Scholar